Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome - a phase-II study-Reference-Cited by-同舟云学术

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome - a phase-II study

Published:2008-12 Issue:5 Volume:143 Page:707-715
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Metzgeroth Georgia,Walz Christoph,Erben Philipp,Popp Helena,Schmitt-Graeff Annette,Haferlach Claudia,Fabarius Alice,Schnittger Susanne,Grimwade David,Cross Nicholas C. P.,Hehlmann Rüdiger,Hochhaus Andreas,Reiter Andreas

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2008.07294.x/fullpdf

Reference27 articles.

1. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta;Apperley;The New England Journal of Medicine,2002

2. The efficacy of imatinib mesylate in patients with FIP1l1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study;Baccarani;Haematologica,2007

3. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature;Chusid;Medicine (Baltimore),1975

4. FIP1L1-PDGFRA-negative hypereosinophilic syndrome: not the usual suspects;Cools;Haematologica,2005

5. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome;Cools;The New England Journal of Medicine,2003

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiology and prognostic nomogram for chronic eosinophilic leukemia: a population-based study using the SEER database;Scientific Reports;2024-02-26

2. Epidemiology and Nomogram Development for Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL-NOS): Insights from the SEER Database;2023-10-02

3. Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?;Blood Reviews;2023-03

4. False-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay;Acta Haematologica;2023

5. Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas;Frontiers in Oncology;2022-11-17